Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker

Simple item page
dc.contributor.authorCruickshank, Tess
dc.contributor.authorMacDonald, Teresa M
dc.contributor.authorWalker, Susan P
dc.contributor.authorKeenan, Emerson
dc.contributor.authorDane, Kirsten
dc.contributor.authorMiddleton, Anna
dc.contributor.authorKyritsis, Valerie
dc.contributor.authorMyers, Jenny
dc.contributor.authorCluver, Catherine
dc.contributor.authorHastie, Roxanne
dc.contributor.authorBergman, Lina
dc.contributor.authorGarcha, Damanpreet
dc.contributor.authorCannon, Ping
dc.contributor.authorMurray, Elizabeth
dc.contributor.authorNguyen, Tuong‐Vi
dc.contributor.authorHiscock, Richard
dc.contributor.authorPritchard, Natasha
dc.contributor.authorHannan, Natalie J
dc.contributor.authorTong, Stephen
dc.contributor.authorKaitu’u‐Lino, Tu’uhevaha J
dc.date.accessioned2024-10-17T07:46:17Z
dc.date.available2024-10-17T07:46:17Z
dc.date.issued2021-08-17
dc.description.abstractBackground We investigated the biomarker potential of growth differentiation factor 15 (GDF-15), a stress response protein highly expressed in placenta, to predict preeclampsia. Methods and Results In 2 prospective cohorts (cohort 1: 960 controls, 39 women who developed preeclampsia; cohort 2: 950 controls, 41 developed preeclampsia), plasma concentrations of GDF-15 at 36 weeks' gestation were significantly increased among those who developed preeclampsia (<i>P</i><0.001), area under the receiver operating characteristic curves (AUC) of 0.66 and 0.71, respectively. In cohort 2 a ratio of sFlt-1/PlGF (a clinical biomarker for preeclampsia) had a sensitivity of 61.0% at 83.2% specificity to predict those who will develop preeclampsia (AUC of 0.79). A ratio of GDF-15×sFlt-1/PlGF yielded a sensitivity of 68.3% at 83.2% specificity (AUC of 0.82). GDF-15 was consistently elevated across a number of international cohorts: levels were higher in placenta and blood from women delivering <34 weeks' gestation due to preterm preeclampsia in Melbourne, Australia; and in the blood at 26 to 32 weeks' gestation among 57 women attending the Manchester Antenatal Vascular Service (MAViS, UK) who developed preeclampsia (<i>P</i>=0.0002), compared with 176 controls. In the Preeclampsia Obstetric adVerse Events biobank (PROVE, South Africa), plasma GDF-15 was significantly increased in women with preeclampsia with severe features (<i>P</i>=0.02; n=14) compared to controls (n=14). Conclusions We conclude circulating GDF-15 is elevated among women more likely to develop preeclampsia or diagnosed with the condition. It may have value as a clinical biomarker, including the potential to improve the sensitivity of sFlt-1/PlGF ratio.
dc.identifier.issn2047-9980
dc.identifier.otherhttps://doi.org/10.1161/jaha.120.020302
dc.identifier.urihttps://scholar.sun.ac.za/handle/10019.1/131308
dc.language.isoen
dc.publisherWolters Kluwer
dc.titleCirculating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker
dc.typeArticle
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Plain Text
Description:
Download
Collections
Research Output - SU Research Articles